ArticleJournal of the American Heart Association2025
Soluble Triggering Receptor Expressed on Myeloid Cells 2 as a Promising Biomarker for Poststroke Depression After Acute Ischemic Stroke.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01840072 (Inner Mongolia Stroke Project A Randomized Controlled Trial of Immediate Blood Pressure Reduction on Death and Major Disability in Patients With Acute Ischemic Stroke in China), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Inner Mongolia Stroke Project A Randomized Controlled Trial of Immediate Blood Pressure Reduction on Death and Major Disability in Patients With Acute Ischemic Stroke in China
Who cites it
3 citing papers in PubMed.
- High plasma levels of soluble triggering receptor expressed on Myeloid Cells 2 were associated with depression in patients with newly diagnosed type 2 diabetes mellitus.Journal of clinical & translational endocrinology · 2026Article
- Microglial Immunometabolic Remodeling After Ischemic Stroke: The Interplay Between Mitochondrial Stress and the Ischemic Microenvironment.Translational stroke research · 2026Review
- Microglia-neuron communication in ischemic stroke: from homeostatic signaling to pathological remodeling and therapeutic targeting.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSoluble triggering receptor expressed on myeloid cells 2 (sTREM2) was reported to induce inflammatory responses, enhance microglial survival, and contribute to the development of neurodegenerative disorders. We aimed to prospectively investigate the association between plasma sTREM2 levels and poststroke depression (PSD).
methodsWe measured plasma sTREM2 levels in 590 patients with ischemic stroke from 7 participating hospitals of the CATIS (China Antihypertensive Trial in Acute Ischemic Stroke) trial. The 24-item Hamilton Rating Scale for Depression was used to assess depression at 3 months after ischemic stroke onset, and PSD was defined as a score of ≥8. The predictive performance of sTREM2 was evaluated by calculating the net reclassification index and integrated discrimination improvement. Random forest regression model was used to assess the importance of sTREM2, clinical variables, and other potential biomarkers.
resultsOf the 590 participants, 229 (38.8%) patients experienced PSD. The multivariable-adjusted odds ratio for the highest quartile of sTREM2 compared with the lowest quartile was 1.98 (95% CI, 1.16-3.37) for PSD. Multiple adjusted spline regression analysis confirmed the linear dose-response relationship between sTREM2 levels and PSD (
conclusionsThe present study demonstrated that elevated plasma sTREM2 levels were associated with an increased risk of PSD, suggesting that sTREM2 may be a promising prognostic biomarker for PSD. REGISTRATION: URL: https://clinicaltrials.gov; Unique identifier: NCT01840072.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.